Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,818
  • Shares Outstanding, K 12,886
  • Annual Sales, $ 230 K
  • Annual Income, $ -6,660 K
  • 60-Month Beta 0.99
  • Price/Sales 219.66
  • Price/Cash Flow N/A
  • Price/Book 3.99
Trade LEXX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 08/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.12
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.52 +34.13%
on 06/27/24
3.41 -0.88%
on 07/26/24
+0.77 (+29.50%)
since 06/26/24
3-Month
2.32 +45.69%
on 04/29/24
4.44 -23.87%
on 06/03/24
+1.03 (+43.83%)
since 04/26/24
52-Week
0.77 +338.96%
on 07/27/23
6.85 -50.66%
on 03/11/24
+2.61 (+337.14%)
since 07/26/23

Most Recent Stories

More News
Lexaria (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2. Lexaria’s patented DehydraTECH(TM)...

LEXX : 3.38 (+9.39%)
Lexaria (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal...

LEXX : 3.38 (+9.39%)
LEXXW : 1.1900 (+8.18%)
Lexaria (NASDAQ: LEXX) Reports Issuance of Three New Patents

Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream...

LEXX : 3.38 (+9.39%)
Lexaria Bioscience (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s...

LEXX : 3.38 (+9.39%)
LEXXW : 1.1900 (+8.18%)
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

DehydraTECH appears to work with a second GLP-1 drug - liraglutide

LEXX : 3.38 (+9.39%)
LEXXW : 1.1900 (+8.18%)
Lexaria Bioscience (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the hiring of a contract research organization (“CRO”) that will be responsible for overseeing the...

LEXX : 3.38 (+9.39%)
Lexaria Bioscience (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that human pilot study #2, GLP-1-H24-2, has now completed all dosing. The final DehydraTECH study...

LEXX : 3.38 (+9.39%)
Lexaria Bioscience (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced three new patent awards. In the European Union, the company received a new patent in Lexaria’s...

LEXX : 3.38 (+9.39%)
LEXXW : 1.1900 (+8.18%)
Lexaria Bioscience (NASDAQ: LEXX) Eyeing Strategic Partnering with Leading GLP-1 Players

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic...

LEXXW : 1.1900 (+8.18%)
LEXX : 3.38 (+9.39%)
Lexaria Bioscience (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2, GLP-1-H24-2. The study...

LEXX : 3.38 (+9.39%)

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 3.87
2nd Resistance Point 3.64
1st Resistance Point 3.51
Last Price 3.38
1st Support Level 3.15
2nd Support Level 2.92
3rd Support Level 2.79

See More

52-Week High 6.85
Fibonacci 61.8% 4.53
Fibonacci 50% 3.81
Last Price 3.38
Fibonacci 38.2% 3.09
52-Week Low 0.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar